Guardant Health Q2 revenue beats estimates, lifts 2026 outlook

Guardant Health

30/07/2026 21:16

Overview
US precision oncology firm's Q2 revenue rose 44%, beating analyst expectations
Adjusted loss per share for Q2 slightly missed analyst estimates
Company raised 2026 revenue guidance on strong Shield screening growth and FDA approvals

Outlook
Guardant Health raises 2026 revenue guidance to $1.34-$1.36 bln, up from $1.30-$1.32 bln
Company expects 2026 screening revenue of $218-$230 mln, driven by Shield volume of 270,000-285,000 tests
Guardant Health sees 2026 non-GAAP gross margin at 64%-65%

Result Drivers
ONCOLOGY VOLUME - Oncology revenue rose 38%, driven mainly by a 63% increase in oncology test volume
SHIELD SCREENING - Screening revenue grew over 250%, driven by Shield test volume rising to 66,000 from 16,000 in the prior year
FDA APPROVALS & COVERAGE - Recent FDA approvals and expanded insurance coverage for Shield supported growth, according to co-CEOs

Company press release: ID:nBw9XsyTZa

Key Details
Metric
Beat/Miss
Actual
Consensus Estimate
Q2 Revenue
Beat
$335 mln
$314.23 mln (21 Analysts)
Q2 Adjusted Loss Per Share
Miss
$0.42
$0.41 (18 Analysts)
Q2 Loss Per Share
 
$0.90
 
Q2 Adjusted Net Loss
Miss
$56.20 mln
$54.29 mln (12 Analysts)
Q2 Adjusted EBITDA
Miss
-$55.90 mln
-$50.28 mln (16 Analysts)

Analyst Coverage
The current average analyst rating on the shares is "buy" and the breakdown of recommendations is 25 "strong buy" or "buy", 2 "hold" and no "sell" or "strong sell"
The average consensus recommendation for the medical equipment, supplies & distribution peer group is "buy"
Wall Street's median 12-month price target for Guardant Health Inc is $175.00, about 21.5% above its July 29 closing price of $144.07

Reuters Recommended Reads
July 28 - NeoGenomics Q2 revenue beats estimates, raises outlook
July 27 - Champions Oncology Q4 revenue rises; margin improves driven by cost discipline
July 28 - US FDA staff cast doubt on Replimune cancer drug's benefit; shares slide

For questions concerning the data in this report, contact Estimates.Support@lseg.com. For any other questions or feedback, contact reuters.support@thomsonreuters.com.

(This story was created using Reuters automation and AI based on LSEG and company data. It was checked and edited by a Reuters journalist prior to publication.)